News and Insights
The latest news and insights from Genoa Healthcare.
- Behavioral Health
- Clinical Insights
- Treatment
8 frequently asked questions on long-acting injectables
Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, answered frequently asked questions about long-acting injectables (LAIs) and how they can support the people you serve....
- Apr 22nd, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Quick guide to recently approved behavioral health medications
Keeping up with new and emerging treatment options for your consumers can be difficult. Genoa Healthcare’s Tim Krause, PharmD, compiled a quick guide to share the latest on recently approved...
- Apr 16th, 2025
- Clinical Insights
- Treatment
Long-acting injectables in practice: What providers need to know
Genoa Healthcare recently hosted a webinar where Senior Product Manager Blake Shoemaker, PharmD, discussed long-acting injectables (LAIs) in practice. Watch the recording below for an overview on benefits, challenges and...
- Apr 10th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Why medication-assisted treatment is essential for improving patient outcomes
1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....
- Mar 28th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Feb 24th, 2025
- Clinical Insights
- Treatment
RELEXXII®: 6 things to know about the new FDA-approved treatment for ADHD
Staying on top of new medication options for your consumers living with ADHD can be difficult. Learn more about the new FDA-approved medication RELEXXII®, a long-acting formulation of methylphenidate. 1....
- Feb 11th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
4 things to know about Spravato® (Intranasal esketamine)
On January 21, 2025, the FDA approved Spravato® nasal spray as the first and only monotherapy for adults living with TRD. The new label expansion will offer greater flexibility in...
- Jan 28th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
- Jan 24th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Brixadi®: 3 things to know about the buprenorphine treatment option
Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...
- Oct 30th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Drug trends in behavioral health: What you need to know
Genoa Healthcare recently hosted a webinar where Pharmaceutical Program Manager Allie Butler, PharmD, and Clinical Pharmacist Cameron Yenney, PharmD, discussed the latest drug trends in behavioral health. Watch the recording...
- Oct 11th, 2024